New obesity drug GZR18 under microscope: how does it interact with common meds?

NCT ID NCT07128888

Recruiting now Disease control Sponsor: Gan & Lee Pharmaceuticals. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests GZR18, an injectable drug for obesity or overweight, in 60 Chinese adults. Researchers want to see how it affects stomach emptying and whether it changes how the body processes digoxin (heart medication), rosuvastatin (cholesterol drug), and warfarin (blood thinner). Participants receive GZR18 for 16 weeks, then take the other drugs for 6 weeks while being monitored. The goal is to understand safety and dosing, not to treat obesity directly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GZR18 injection
What this could lead to: If successful, this study could help determine safe use of GZR18 with common medications like heart drugs, statins, and blood thinners in people with obesity.
What could go wrong: This is an early Phase 1 trial with only 60 participants, so results may not apply to everyone. The main goal is safety and drug interaction, not weight loss or disease treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OR OVERWEIGHT

Contacts and locations

Locations

Study site 01
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.